This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erali, M.
Right arrow Articles by Hillyard, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erali, M.
Right arrow Articles by Hillyard, D. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2001, p. 2157-2165, Vol. 39, No. 6
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.6.2157-2165.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Human Immunodeficiency Virus Type 1 Drug Resistance Testing: a Comparison of Three Sequence-Based Methods

Maria Erali,1,* Sam Page,1 Larry G. Reimer,1,2 and David R. Hillyard1,2

ARUP Institute for Clinical and Experimental Pathology,1 and Department of Pathology, University of Utah Health Sciences Center,2 Salt Lake City, Utah

Received 29 November 2000/Returned for modification 30 January 2001/Accepted 14 March 2001

The use of genotypic assays for determining drug resistance in human immunodeficiency virus (HIV) type 1 (HIV-1)-infected patients is increasing. These tests lack standardization and validation. The aim of this study was to evaluate several tests used for the determination of HIV-1 drug resistance. Two genotypic tests, the Visible Genetics TruGene HIV-1 Genotyping Kit and the Applied Biosystems HIV Genotyping System, were compared using 22 clinical samples. Genotyping results were also obtained from an independent reference laboratory. The Visible Genetics and Applied Biosystems genotyping tests identified similar mutations when differences in the drug databases and reference strains were taken into account, and 19 of 21 samples were equivalent. The concordance between the two assays was 99% (249 of 252 mutation sites). Mutations identified by the reference laboratory varied the most among those identified by the three genotypic tests, possibly because of differences in the databases. The concordance of the reference laboratory results with the results of the other two assays was 80% (201 of 252). Samples with 500 to 750 HIV RNA copies/ml could be sequenced by the Visible Genetics and Applied Biosystems assays using 1 ml of input. The Visible Genetics and Applied Biosystems assays both generated an accurate sequence. However, the throughput of the Visible Genetics assay is more limited and may require additional instruments. The two assays differ technically but are similar in overall complexity. Data analysis in the two assays is straightforward, but only the reports provided by Visible Genetics contain information relating mutations to drug resistance. HIV drug resistance genotyping by sequencing is a complex technology which presents a challenge for analysis, interpretation, and reporting.


* Corresponding author. Mailing address: ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108. Phone: (801) 583-2787, ext. 2312. Fax: (801) 584-5207. E-mail: eralimc{at}arup-lab.com.


Journal of Clinical Microbiology, June 2001, p. 2157-2165, Vol. 39, No. 6
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.6.2157-2165.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Paar, C., Palmetshofer, C., Flieger, K., Geit, M., Kaiser, R., Stekel, H., Berg, J. (2008). Genotypic Antiretroviral Resistance Testing for Human Immunodeficiency Virus Type 1 Integrase Inhibitors by Use of the TruGene Sequencing System. J. Clin. Microbiol. 46: 4087-4090 [Abstract] [Full Text]  
  • Tong, C. Y. W., Mullen, J., Kulasegaram, R., De Ruiter, A., O'Shea, S., Chrystie, I. L. (2005). Genotyping of B and Non-B Subtypes of Human Immunodeficiency Virus Type 1. J. Clin. Microbiol. 43: 4623-4627 [Abstract] [Full Text]  
  • Huang, D. D., Bremer, J. W., Brambilla, D. J., Palumbo, P. E., for the Pediatric ACTG Sequencing Working Group, (2005). Model for Assessment of Proficiency of Human Immunodeficiency Virus Type 1 Sequencing-Based Genotypic Antiretroviral Assays. J. Clin. Microbiol. 43: 3963-3970 [Abstract] [Full Text]  
  • Saag, M. S., Cahn, P., Raffi, F., Wolff, M., Pearce, D., Molina, J.-M., Powderly, W., Shaw, A. L., Mondou, E., Hinkle, J., Borroto-Esoda, K., Quinn, J. B., Barry, D. W., Rousseau, F., for the FTC-301A Study Team, (2004). Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. JAMA 292: 180-189 [Abstract] [Full Text]  
  • Galli, R. A., Sattha, B., Wynhoven, B., O'Shaughnessy, M. V., Harrigan, P. R. (2003). Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance. J. Clin. Microbiol. 41: 2900-2907 [Abstract] [Full Text]  
  • Huang, D. D., Eshleman, S. H., Brambilla, D. J., Palumbo, P. E., Bremer, J. W. (2003). Evaluation of the Editing Process in Human Immunodeficiency Virus Type 1 Genotyping. J. Clin. Microbiol. 41: 3265-3272 [Abstract] [Full Text]  
  • Jagodzinski, L. L., Cooley, J. D., Weber, M., Michael, N. L. (2003). Performance Characteristics of Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping Systems in Sequence-Based Analysis of Subtypes Other than HIV-1 Subtype B. J. Clin. Microbiol. 41: 998-1003 [Abstract] [Full Text]  
  • Sayer, D. C., Land, S., Gizzarelli, L., French, M., Hales, G., Emery, S., Christiansen, F. T., Dax, E. M. (2003). Quality Assessment Program for Genotypic Antiretroviral Testing Improves Detection of Drug Resistance Mutations. J. Clin. Microbiol. 41: 227-236 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]